We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

How Much Further Can AstraZeneca plc, Unilever plc And Rolls-Royce Holding PLC Fall?

Is it time to load up on AstraZeneca plc (LON: AZN), Unilever plc (LON: ULVR) and Rolls-Royce Holding PLC (LON: RR)?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

What do you do when quality shares fall in price without the company itself doing anything wrong? If you’re a long-term investor, you buy, of course!

Look at drugs giant AstraZeneca (LSE: AZN). It was out of favour for a while when both it and rival GlaxoSmithKline were hit by the loss of patents on key products and increasing generic competition, but investors took a quick shine to new boss Pascal Soriot and his back-to-basics turnaround plan and the share price started picking up again.

XXX

But with the latest China-led stock market crunch, we’ve seen AstraZeneca shares turn tail once more — the price is down more than 8% in just the past five days, to 3,964p, and it’s fallen 18% since 2015’s high point in April. The price fall brings AstraZeneca’s forward P/E based on 2016 forecasts down to 15, which looks cheap around the expected bottom in the earnings cycle, especially with a 4.4% dividend yield forecast.

If you thought AstraZeneca was worth buying a week ago, then surely it’s a better bargain now, isn’t it?

Time to clean up?

Unilever (LSE: ULVR) is another stalwart whose price has dipped, with a loss of 13% since 6 August, to 2,572p as I write. To be fair, Unilever does sell a fair bit of its soapy things in the Asian region, but slowing Chinese growth is unlikely to cause any real upset. With EPS predicted to grow at 10% this year, Unilever shares are now on a forward P/E of around 20 — though forecasts could be downgraded a little.

Unilever always looks too highly priced to me and I fear there could be a little more downside yet, but solid defensive stocks are often afforded such premiums by institutional investors. So if you’re looking to pick up such shares in the dips, now could be your chance.

One attraction of Unilever is its dividends, and the share price fall has upped the forecast yields to 3.2% and 3.4% for this year and next. It’s not one of the biggest yields on the market, but it should be well covered by earnings and is generally considered very reliable.

Aerospace bargain?

Rolls-Royce (LSE: RR) shares have been falling after the company that has traditionally just kept on growing its earnings shocked the market with a string of profit warnings. From a peak of nearly £13 in January 2014, the shares have lost a whopping 44% to trade at 721p as I write – a little up from the 685.5p low hit on Monday in the immediate wake of the China crash.

There’s still a couple of years of earnings falls forecast for Rolls-Royce, but with a 2016 P/E of 16 and with dividends set to yield a decently-covered 3% or so, this looks like another that could be undervalued at the bottom of a cycle.

The fundamental nature of these three is unaffected by this week’s market fallout, and they’re just the same companies they were last week — but there will still be people selling out in fear of further irrational panic.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK owns and has recommended Unilever, and has recommended Glaxo. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »